3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
147
Carcinoma, Neuroendocrine
57
Thyroid Cancer, Papillary
54
Pheochromocytoma
52
Paraganglioma
42
Thyroid Neoplasms
41
Pituitary Neoplasms
40
Neoplasms
32
Adrenocortical Carcinoma
31
Multiple Endocrine Neoplasia Type 1
29
Gastro-enteropancreatic neuroendocrine tumor
29
Thyroid Carcinoma, Anaplastic
23
Lung Neoplasms
22
Small Cell Lung Carcinoma
21
Sarcoma
20
Carcinoid Tumor
20
Breast Neoplasms
19
Neoplasm Metastasis
18
Carcinoma, Non-Small-Cell Lung
18
Adenoma, Islet Cell
18
Melanoma
17
Carcinoma, Hepatocellular
17
Pancreatic Neoplasms
16
Colorectal Neoplasms
16
Adrenal Gland Neoplasms
16
Prostatic Neoplasms
15
Ovarian Neoplasms
15
Neuroblastoma
15
Carcinoma, Renal Cell
15
Adenocarcinoma, Follicular
15
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Endocrine
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled